Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Indian Drugmaker Draws Two FDA Warning Letters Over Untested Glycerin

  • Post author:PacConAdmin
  • Post published:May 24, 2023
  • Post category:Drug Industry Daily

India-based drugmaker Champaklal Maganlal Homeo Pharmacy (CMHP) has drawn two FDA warning letters in recent weeks over untested glycerin in gastrointestinal products for children, among other serious current good manufacturing…

Continue ReadingIndian Drugmaker Draws Two FDA Warning Letters Over Untested Glycerin

FDA Advises on Using Generally Accepted Scientific Knowledge in Applications

  • Post author:PacConAdmin
  • Post published:May 24, 2023
  • Post category:Drug Industry Daily

The FDA has spelled out when drugmakers may use generally accepted scientific knowledge (GASK) to support a drug or biologic application, in a new draft guidance. Source: Drug Industry Daily

Continue ReadingFDA Advises on Using Generally Accepted Scientific Knowledge in Applications

ICH Advances Draft Guideline on Good Clinical Practice

  • Post author:PacConAdmin
  • Post published:May 24, 2023
  • Post category:Drug Industry Daily

The International Council on Harmonisation (ICH) has released a draft guideline on good clinical practice (GCP), designed to facilitate acceptance of clinical trial data by ICH member countries and regions.…

Continue ReadingICH Advances Draft Guideline on Good Clinical Practice

Meeting Planner — Week of May 22, 2023

  • Post author:PacConAdmin
  • Post published:May 24, 2023
  • Post category:Drug Industry Daily

Upcoming events in the coming weeks include six FDA advisory committee meetings as well as webinars and conferences on subjects ranging from advanced gene and cell therapy, ICH E8 R1…

Continue ReadingMeeting Planner — Week of May 22, 2023

Republicans Renew Call for ‘Reciprocity’ in FDA’s Approval Process

  • Post author:PacConAdmin
  • Post published:May 23, 2023
  • Post category:Drug Industry Daily

Republican lawmakers are renewing their push to speed FDA approvals by allowing the agency to automatically approve drugs and devices that have been approved and sold in other developed and…

Continue ReadingRepublicans Renew Call for ‘Reciprocity’ in FDA’s Approval Process

Teva Hit With Class Action Suit for Allegedly Blocking Generic Inhalers

  • Post author:PacConAdmin
  • Post published:May 23, 2023
  • Post category:Drug Industry Daily

The Ironworkers District Council of New England Health and Welfare Fund has filed a class action complaint against Teva Pharmaceuticals accusing the company of a nearly decade-long anticompetitive scheme to…

Continue ReadingTeva Hit With Class Action Suit for Allegedly Blocking Generic Inhalers

Ironwood to Buy VectivBio for $1.15 Billion, Expanding Gastro Portfolio

  • Post author:PacConAdmin
  • Post published:May 23, 2023
  • Post category:Drug Industry Daily

Ironwood Pharmaceuticals is acquiring VectivBio for $1.15 billion, netting a promising late-stage clinical asset aimed at treating severe, rare gastrointestinal conditions. Source: Drug Industry Daily

Continue ReadingIronwood to Buy VectivBio for $1.15 Billion, Expanding Gastro Portfolio

Using Audit Findings to Drive Quality

  • Post author:PacConAdmin
  • Post published:May 23, 2023
  • Post category:Drug Industry Daily

The best organizations use findings from both internal audits and third-party inspections to build knowledge for future improvement — using audit data to improve the audit program itself, says Steven…

Continue ReadingUsing Audit Findings to Drive Quality

Legislative Update — Week of May 22, 2023

  • Post author:PacConAdmin
  • Post published:May 23, 2023
  • Post category:Drug Industry Daily

As the 118th Congress continues, FDAnews will track important pending legislation to keep you updated on regulations that could impact your business. Source: Drug Industry Daily

Continue ReadingLegislative Update — Week of May 22, 2023

Centaur Pharmaceuticals Gets 483 for Hiding, Shredding Documents, Other Quality Lapses

  • Post author:PacConAdmin
  • Post published:May 22, 2023
  • Post category:Drug Industry Daily

The FDA slapped Centaur Pharmaceuticals with a 10-observation Form 483 after investigators observed destruction of good manufacturing practice (GMP) documents, among other serious lapses. Source: Drug Industry Daily

Continue ReadingCentaur Pharmaceuticals Gets 483 for Hiding, Shredding Documents, Other Quality Lapses
  • Go to the previous page
  • 1
  • …
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.